CYTOKINETICS, INCORPORATED Proceeds from Convertible Debt
CYTOKINETICS, INCORPORATED (CYTK) reported Proceeds from Convertible Debt of $729.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for the quarter ending 2022-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for fiscal 2025 was $729.46M.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for fiscal 2024 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED proceeds from convertible debt for fiscal 2022 was $523.59M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $729.46M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $729.46M 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $523.59M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $523.59M 10-Q · filed 2023-11-03 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |